FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Study Summary

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.

Conditions

Advanced Hematologic Malignancy Relapsed Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Relapsed Myelodysplastic Syndromes Refractory Myelodysplastic Syndromes Relapsed Chronic Myelomonocytic Leukemia Refractory Chronic Myelomonocytic Leukemia

Interventions / Drugs

FHD-286 Low Dose Cytarabine Decitabine

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment144 participants

Primary Completion—

Lead SponsorFoghorn Therapeutics Inc.

Data Retrieved2026-04-11 04:14:07.472758+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.